1068 Results for "

obesity

" in MedChemExpress (MCE) Product Catalog:

Products (1068)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

202

Rosiglitazone

202 Publications Verification

Cat. No.: HY-17386

CAS No.: 122320-73-4

Synonyms: BRL 49653

Target:

PPAR TRP Channel Autophagy Ferroptosis Apoptosis

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM), with blood-brain barrier permeability. Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

201

Rosiglitazone hydrochloride

201 Cited Publications

Cat. No.: HY-17386A

CAS No.: 302543-62-0

Synonyms: BRL 49653 hydrochloride

Target:

PPAR TRP Channel Autophagy Ferroptosis Apoptosis

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

198

Rosiglitazone potassium

198 Cited Publications

Cat. No.: HY-17386B

CAS No.: 316371-84-3

Synonyms: BRL 49653 potassium

Target:

PPAR TRP Channel Autophagy Apoptosis Ferroptosis

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

NAD sodium

54 Cited Publications

Cat. No.: HY-B0445A

CAS No.: 20111-18-6

Synonyms: β-DPN sodium; β-NAD sodium; β-Nicotinamide Adenine Dinucleotide sodium

NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Semaglutide

53 Cited Publications

Cat. No.: HY-114118

CAS No.: 910463-68-2

Purity: 99.84%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Semaglutide acetate

53 Cited Publications

Cat. No.: HY-114118B

CAS No.: 1997361-85-9

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Semaglutide TFA

53 Cited Publications

Cat. No.: HY-114118A

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare